Sanofi (SNY) Q3 2026 Earnings Call Transcript

Sanofi reported Q3 2026 sales of €14.4 billion, up 14.3% at constant exchange rates, and business EPS of €3.55, up 19.6%; its business operating income margin expanded 1.9 percentage points to 37.6%. The company raised full-year 2026 guidance to 13%-15% sales growth and 15%-17% business EPS growth, citing commercial momentum, while Dupixent sales rose 34.8% to €5.7 billion. Sanofi expanded its Regeneron alliance with a $1 billion upfront payment and up to $7 billion in potential milestones for four long-acting antibodies; management also flagged 2027 pricing headwinds, about €1.3 billion of sales reductions from portfolio transactions, and the need to prepare for Dupixent's loss of exclusivity after 2031.

Analysis

The quarter supports a quality-of-earnings distinction: demand appears to be the durable engine, while gross-to-net cleanup and favorable pricing amplified reported growth and should not be extrapolated. That makes the upgraded 2026 outlook credible but leaves the 2027 setup less clean: negative pricing, a higher comparison base, and roughly €1.3bn of portfolio-related sales reduction can slow reported growth even if underlying demand and operating leverage hold. The key test is whether BOI margin still expands as management says, not whether headline sales growth stays at 2026 levels.

Strategically, Sanofi is exchanging near-term pipeline certainty for external innovation: the Regeneron alliance adds options against Dupixent concentration, but the long-acting IL-13 asset is early-stage and registrational studies are not expected before late 2027/early 2028. The €1bn upfront commitment, contingent milestones, and rising Dupixent profit share compete for capital with acquisitions and dividends. Meanwhile, the mature-portfolio exit may improve business quality but makes revenue trends harder to read. The central contrarian risk is that investors price the next-generation franchise as a credible LOE bridge before clinical differentiation and launch timing are established. Conversely, fear of the LOE may be premature given the stated 2031-plus horizon and continuing demand expansion.

Near term, the December strategy update is the catalyst: seek quantified capital-allocation guardrails, replacement revenue, and disease-area priorities. Over 6–18 months, clinical execution and acquired-asset discipline matter more than AI or China productivity claims, which remain unverified. Thesis weakens if 2027 BOI margin fails to expand, Dupixent demand decelerates materially, or deal activity pressures credit quality. No reliable valuation or consensus data are supplied, so avoid asserting mispricing.

Key Decisions for Investors

• Construct a measured long SNY position on post-results weakness rather than chasing the upgrade; reassess after the December strategy update. Thesis: durable demand and operating leverage offset transitory reported-growth headwinds. Falsify if 2027 BOI margin does not expand or management materially lowers its growth framework.
• Track 2027 underlying sales separately from reported sales: strip out the disclosed portfolio exits and distinguish demand from pricing and gross-to-net. Treat another quarter of exceptional gross-to-net benefit as upside, not a base-case assumption.
• Keep the Dupixent replacement thesis on watch, not in the base case: monitor phase I safety/PK and the timing and design of registrational studies for the long-acting anti-IL-13. Revisit only when differentiation, launch timing, and economics are better evidenced.
• Monitor balance-sheet and capital-allocation disclosures around the €1bn alliance payment, contingent milestones, and any bolt-on deals. Escalate risk if acquisitions compromise investment-grade discipline or dividend commitments; no TEVA pair is warranted from the supplied evidence.